144 related articles for article (PubMed ID: 17496369)
21. The socioeconomic consequences of multiple sclerosis: a controlled national study.
Jennum P; Wanscher B; Frederiksen J; Kjellberg J
Eur Neuropsychopharmacol; 2012 Jan; 22(1):36-43. PubMed ID: 21669514
[TBL] [Abstract][Full Text] [Related]
22. [Health economics analysis of diabetes is necessary. It facilitates decision-making and international comparison].
Henriksson F; Agardh CD; Berne C; Bolinder J; Jönsson B
Lakartidningen; 1999 Sep; 96(37):3915-6, 3919. PubMed ID: 10522101
[TBL] [Abstract][Full Text] [Related]
23. Direct and indirect costs of asthma in Canada, 1990.
Krahn MD; Berka C; Langlois P; Detsky AS
CMAJ; 1996 Mar; 154(6):821-31. PubMed ID: 8634960
[TBL] [Abstract][Full Text] [Related]
24. The annual impact of seasonal influenza in the US: measuring disease burden and costs.
Molinari NA; Ortega-Sanchez IR; Messonnier ML; Thompson WW; Wortley PM; Weintraub E; Bridges CB
Vaccine; 2007 Jun; 25(27):5086-96. PubMed ID: 17544181
[TBL] [Abstract][Full Text] [Related]
25. Economic burden of diabetic patients in India: A review.
Bansode B; Jungari DS
Diabetes Metab Syndr; 2019; 13(4):2469-2472. PubMed ID: 31405662
[TBL] [Abstract][Full Text] [Related]
26. Economic evaluations and diabetes.
Pathak DS; Burke TA
Pharm Pract Manag Q; 1998 Jan; 17(4):17-24. PubMed ID: 10174745
[TBL] [Abstract][Full Text] [Related]
27. Cost of care of schizophrenia: a study of Indian out-patient attenders.
Grover S; Avasthi A; Chakrabarti S; Bhansali A; Kulhara P
Acta Psychiatr Scand; 2005 Jul; 112(1):54-63. PubMed ID: 15952946
[TBL] [Abstract][Full Text] [Related]
28. Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN).
Houle SK; Chuck AW; McAlister FA; Tsuyuki RT
Pharmacotherapy; 2012 Jun; 32(6):527-37. PubMed ID: 22552863
[TBL] [Abstract][Full Text] [Related]
29. Considerations in assessing effectiveness and costs of diabetes care: lessons from DARTS.
Morris AD
Diabetes Metab Res Rev; 2002; 18 Suppl 3():S32-5. PubMed ID: 12324983
[TBL] [Abstract][Full Text] [Related]
30. Measuring the economic and social consequences of CVDs and diabetes in India and Pakistan.
Govender VM; Ghaffar A; Nishtar S
Biosci Trends; 2007 Dec; 1(3):121-7. PubMed ID: 20103881
[TBL] [Abstract][Full Text] [Related]
31. Cost of depression in Europe.
Sobocki P; Jönsson B; Angst J; Rehnberg C
J Ment Health Policy Econ; 2006 Jun; 9(2):87-98. PubMed ID: 17007486
[TBL] [Abstract][Full Text] [Related]
32. Economic cost of cataract surgery procedures in an established eye care centre in Southern India.
Muralikrishnan R; Venkatesh R; Prajna NV; Frick KD
Ophthalmic Epidemiol; 2004 Dec; 11(5):369-80. PubMed ID: 15590584
[TBL] [Abstract][Full Text] [Related]
33. Epidemiology of complications and total treatment costs from diagnosis of Type 2 diabetes in Germany (ROSSO 4).
Martin S; Schramm W; Schneider B; Neeser K; Weber C; Lodwig V; Heinemann L; Scherbaum WA; Kolb H
Exp Clin Endocrinol Diabetes; 2007 Sep; 115(8):495-501. PubMed ID: 17853332
[TBL] [Abstract][Full Text] [Related]
34. Increasing expenditure on health care incurred by diabetic subjects in a developing country: a study from India.
Ramachandran A; Ramachandran S; Snehalatha C; Augustine C; Murugesan N; Viswanathan V; Kapur A; Williams R
Diabetes Care; 2007 Feb; 30(2):252-6. PubMed ID: 17259490
[TBL] [Abstract][Full Text] [Related]
35. Economic costs associated with acute attacks and long-term management of hereditary angioedema.
Wilson DA; Bork K; Shea EP; Rentz AM; Blaustein MB; Pullman WE
Ann Allergy Asthma Immunol; 2010 Apr; 104(4):314-20. PubMed ID: 20408341
[TBL] [Abstract][Full Text] [Related]
36. Cost of treating seriously mentally ill persons with HIV following highly active retroviral therapy (HAART).
Rothbard AB; Lee S; Blank MB
J Ment Health Policy Econ; 2009 Dec; 12(4):187-94. PubMed ID: 20195006
[TBL] [Abstract][Full Text] [Related]
37. The economic costs of severe anaphylaxis in France: an inquiry carried out by the Allergy Vigilance Network.
Flabbee J; Petit N; Jay N; Guénard L; Codreanu F; Mazeyrat R; Kanny G; Moneret-Vautrin DA
Allergy; 2008 Mar; 63(3):360-5. PubMed ID: 18269678
[TBL] [Abstract][Full Text] [Related]
38. Economic considerations in overactive bladder.
Hu TW; Wagner TH
Am J Manag Care; 2000 Jul; 6(11 Suppl):S591-8. PubMed ID: 11183902
[TBL] [Abstract][Full Text] [Related]
39. Major complications have an impact on total annual medical cost of diabetes: results of a database analysis.
Morsanutto A; Berto P; Lopatriello S; Gelisio R; Voinovich D; Cippo PP; Mantovani LG
J Diabetes Complications; 2006; 20(3):163-9. PubMed ID: 16632236
[TBL] [Abstract][Full Text] [Related]
40. Cost impact of COPD in Japan: opportunities and challenges?
Nishimura S; Zaher C
Respirology; 2004 Nov; 9(4):466-73. PubMed ID: 15612957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
